Soligenix (SNGX) investor relations material

Executive summary

• Net loss for Q2 2026 was $1.99M, a decrease of $0.71M year-over-year, mainly due to lower R&D expenses after the termination of the FLASH2 trial and HyBryte™ program.

• For the six months ended June 30, 2026, net loss was $4.81M, down $0.84M from the prior year, also driven by reduced R&D costs.

• No revenue was recognized in Q2 or the first half of 2026.

• The company operates two segments: Specialized BioTherapeutics (focus on rare diseases) and Public Health Solutions (biodefense and infectious disease vaccines).

Financial highlights

• Cash and cash equivalents as of June 30, 2026: $9.81M, up from $7.94M at year-end 2025.

• Working capital increased to $6.5M from $5.15M at December 31, 2025.

• R&D expenses for Q2 2026: $0.97M (down from $1.68M in Q2 2025); for six months: $2.76M (down from $3.62M in 2025).

• General and administrative expenses were stable at $1.13M for Q2 and $2.23M for six months.

• Interest income for Q2 2026: $53.6K (down from $69.8K in Q2 2025).

Outlook and guidance

• Management expects continued losses in the foreseeable future, with liquidity needs dependent on operational expenditures for product development.

• Cash runway is projected to support operations into Q2 2028, but substantial doubt remains about the ability to continue as a going concern without additional capital or strategic transactions.

• Plans include seeking further equity, government grants, and strategic partnerships.